<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2017-1-66-71</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-741</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Информационная ценность прокальцитонина в определении природы воспалительной реакции в ревматологии</article-title><trans-title-group xml:lang="en"><trans-title>Informative value of procalcitonin in determining the nature of an inflammatory response in rheumatology</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Теплякова</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Teplyakova</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>620028, Екатеринбург, ул. Репина, 3</p></bio><bio xml:lang="en"><p>3, Repin St., Yekaterinburg 620028</p></bio><email xlink:type="simple">oteplyakova69@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Руднов</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Rudnov</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>620028, Екатеринбург, ул. Репина, 3</p><p>620102, Екатеринбург, ул. Волгоградская, 189</p></bio><bio xml:lang="en"><p>3, Repin St., Yekaterinburg 620028</p><p>189, Volgogradskaya St., Yekaterinburg 620102</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Уральский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Ural State Medical University, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Уральский государственный медицинский университет» Минздрава России&#13;
&#13;
Муниципальное автономное учреждение «Городская клиническая больница №40»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Ural State Medical University, Ministry of Health of Russia&#13;
&#13;
City Clinical Hospital Forty</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>24</day><month>03</month><year>2017</year></pub-date><volume>11</volume><issue>1</issue><fpage>66</fpage><lpage>71</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Теплякова О.В., Руднов В.А., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Теплякова О.В., Руднов В.А.</copyright-holder><copyright-holder xml:lang="en">Teplyakova O.V., Rudnov V.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/741">https://mrj.ima-press.net/mrj/article/view/741</self-uri><abstract><p>Представлен обзор литературы, касающийся использования прокальцитонина (ПКТ) в качестве маркера, обеспечивающего проведение дифференциальной диагностики между диффузными болезнями соединительной ткани, системными васкулитами в активной стадии и проявлениями системной бактериальной инфекции. Уровень дискриминационной значимости ПКТ в большинстве случаев варьирует от 0,1 до 0,5 нг/мл. В то же время установлено, что при некоторых формах системных васкулитов (болезнь Стилла у взрослых, синдром активации макрофагов) уровень ПКТ может соответствовать таковому при системных бактериальных инфекциях. В связи с этим роль ПКТ не следует абсолютизировать – он служит только важным подспорьем при использовании современных методов лучевой, микробиологической и лабораторной диагностики. Повысить диагностическую ценность ПКТ в данных клинических ситуациях возможно при сочетанном определении его содержания в крови и тяжести органной дисфункции по шкале SOFA (Sepsis-related Organ Failure).</p></abstract><trans-abstract xml:lang="en"><p>The paper reviews the literature regarding the use of procalcitonin (PCT) as a marker providing a differential diagnosis between diffuse connective tissue diseases, active systemic vasculitis, and manifestations of systemic bacterial infection. The discriminatory significance of PCT in most cases varies from 0.1 to 0.5 ng/ml. At the same time it has been found that the level of PCT in some forms of systemic vasculitis (adultonset Still's disease, macrophage activation syndrome) may correspond to that in systemic bacterial infections. In this connection, the role of PCT should not be absolutized; it may serve only as a great help using the current methods for X-ray, microbiological, and laboratory investigation. The diagnostic value of PCT in these clinical situations can be enhanced by the combined determination of its blood levels and the severity of organ dysfunction in accordance with the Sepsis-related Organ Failure Assessment (SOFA) scale.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>прокальцитонин</kwd><kwd>диффузные болезни соединительной ткани</kwd><kwd>системные васкулиты</kwd></kwd-group><kwd-group xml:lang="en"><kwd>procalcitonin</kwd><kwd>diffuse connective tissue diseases</kwd><kwd>systemic vasculitis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Shi Y, Peng YM, Hu XY, Wang Y. The utility of initial procalcitonin and procalcitonin clearance for prediction of bacterial infection and outcome in critically ill patients with autoimmune diseases: a prospective observational study. BMC Anesthesiol. 2015 Oct 7;15:137. doi: 10.1186/s12871-015-0122-9.</mixed-citation><mixed-citation xml:lang="en">Shi Y, Peng YM, Hu XY, Wang Y. The utility of initial procalcitonin and procalcitonin clearance for prediction of bacterial infection and outcome in critically ill patients with autoimmune diseases: a prospective observational study. BMC Anesthesiol. 2015 Oct 7;15:137. doi: 10.1186/s12871-015-0122-9.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Muller B, Becker K. Procalcitonin: how a hormone became a marker and mediator of sepsis. Swiss Med Wkly. 2001 Oct 20;131 (41-42):595-602.</mixed-citation><mixed-citation xml:lang="en">Muller B, Becker K. Procalcitonin: how a hormone became a marker and mediator of sepsis. Swiss Med Wkly. 2001 Oct 20;131 (41-42):595-602.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Muller B, White JC, Nylen E, et al. Ubiquitous expression of the calcitonin-1 gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab. 2001 Jan;86(1): 396-404.</mixed-citation><mixed-citation xml:lang="en">Muller B, White JC, Nylen E, et al. Ubiquitous expression of the calcitonin-1 gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab. 2001 Jan;86(1): 396-404.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Becker KL, Nylen ES, White JC, et al. Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. Endocrinol Metab. 2004 Apr;89(4):1512-25.</mixed-citation><mixed-citation xml:lang="en">Becker KL, Nylen ES, White JC, et al. Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. Endocrinol Metab. 2004 Apr;89(4):1512-25.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Meisner M. Procalcitonin – a new, innovative infection parameter. Berlin: Brahms Diagnostica; 1996. P. 3-41.</mixed-citation><mixed-citation xml:lang="en">Meisner M. Procalcitonin – a new, innovative infection parameter. Berlin: Brahms Diagnostica; 1996. P. 3-41.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Assicot M, Gendrel D, Carsin H, et al. High serum procalcitonin concentrations in patienys with sepsis and infection. Lancet. 1993 Feb 27;341(8844):515-8.</mixed-citation><mixed-citation xml:lang="en">Assicot M, Gendrel D, Carsin H, et al. High serum procalcitonin concentrations in patienys with sepsis and infection. Lancet. 1993 Feb 27;341(8844):515-8.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Eberhard OK, Haubitz M, Brunkhorst FM, et al. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody- associated vasculitis) and invasive bacterial infection. Arthritis Rheum. 1997 Jul;40(7):1250-6.</mixed-citation><mixed-citation xml:lang="en">Eberhard OK, Haubitz M, Brunkhorst FM, et al. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody- associated vasculitis) and invasive bacterial infection. Arthritis Rheum. 1997 Jul;40(7):1250-6.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Wu JY, Lee SH, Shen CJ, et al. Use of serum procalcitonin to detect bacterial infection in patients with autoimmune diseases: a systematic review and meta-analysis. Arthritis Rheum. 2012 Sep;64(9):3034-42. doi: 10.1002/art.34512.</mixed-citation><mixed-citation xml:lang="en">Wu JY, Lee SH, Shen CJ, et al. Use of serum procalcitonin to detect bacterial infection in patients with autoimmune diseases: a systematic review and meta-analysis. Arthritis Rheum. 2012 Sep;64(9):3034-42. doi: 10.1002/art.34512.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Lanoix JP, Bourgeois AM, Schmidt J, et al. Serum procalcitonin does not differentiate between infection and disease flare in patients with systemic lupus erythematosus. Lupus. 2011 Feb;20(2):125-30. doi: 10.1177/0961203310378862. Epub 2010 Oct 11.</mixed-citation><mixed-citation xml:lang="en">Lanoix JP, Bourgeois AM, Schmidt J, et al. Serum procalcitonin does not differentiate between infection and disease flare in patients with systemic lupus erythematosus. Lupus. 2011 Feb;20(2):125-30. doi: 10.1177/0961203310378862. Epub 2010 Oct 11.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013 Feb;41(2):580-637. doi: 10.1097/CCM.0b013e31827e83af.</mixed-citation><mixed-citation xml:lang="en">Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013 Feb;41(2):580-637. doi: 10.1097/CCM.0b013e31827e83af.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Тарасова ГМ, Белов БС, Александрова ЕН, Новиков АА. Прокальцитониновый тест при ревматических заболеваниях. Научно-практическая ревматология. 2014;52(4):387- 92. [Tarasova GM, Belov BS, Aleksandrova EN, Novikov AA. Procalcitonin test in rheumatic diseases. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(4):387-92. (In Russ.)]. doi: 10.14412/1995-4484-2014-387-392.</mixed-citation><mixed-citation xml:lang="en">Тарасова ГМ, Белов БС, Александрова ЕН, Новиков АА. Прокальцитониновый тест при ревматических заболеваниях. Научно-практическая ревматология. 2014;52(4):387- 92. [Tarasova GM, Belov BS, Aleksandrova EN, Novikov AA. Procalcitonin test in rheumatic diseases. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(4):387-92. (In Russ.)]. doi: 10.14412/1995-4484-2014-387-392.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Herrmann K, Schinke S, Csernok E, et al. Diagnostic Value of Procalcitonin in ANCAAssociated Vasculitis (AAV) to Differentiate Between Disease Activity, Infection and Drug Hypersensitivity. Open Rheumatol J. 2015 Oct 9;9:71-6. doi: 10.2174/1874312901409010071. eCollection 2015.</mixed-citation><mixed-citation xml:lang="en">Herrmann K, Schinke S, Csernok E, et al. Diagnostic Value of Procalcitonin in ANCAAssociated Vasculitis (AAV) to Differentiate Between Disease Activity, Infection and Drug Hypersensitivity. Open Rheumatol J. 2015 Oct 9;9:71-6. doi: 10.2174/1874312901409010071. eCollection 2015.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Lin CH, Hsieh SC, Keng LT, et al. Prospective Evaluation of Procalcitonin, Soluble Triggering Receptor Expressed on Myeloid Cells-1 and C-Reactive Protein in Febrile Patients with Autoimmune Diseases. PLoS One. 2016 Apr 20;11(4):e0153938. doi: 10.1371/journal.pone.0153938. eCollection 2016.</mixed-citation><mixed-citation xml:lang="en">Lin CH, Hsieh SC, Keng LT, et al. Prospective Evaluation of Procalcitonin, Soluble Triggering Receptor Expressed on Myeloid Cells-1 and C-Reactive Protein in Febrile Patients with Autoimmune Diseases. PLoS One. 2016 Apr 20;11(4):e0153938. doi: 10.1371/journal.pone.0153938. eCollection 2016.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Лапин СВ, Маслянский АЛ, Лазарева НМ и др. Значение количественного определения прокальцитонина для диагностики септических осложнений у больных с аутоиммунными ревматическими заболеваниями. Клиническая лабораторная диагностика. 2013;(1):28-33. [Lapin SV, Maslyanskii AL, Lazareva NM, et al. The value of quantitative determination of procalcitonin for the diagnosis of septic complications in patients with autoimmune rheumatic diseases. Klinicheskaya laboratornaya diagnostika. 2013;(1):28-33. (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Лапин СВ, Маслянский АЛ, Лазарева НМ и др. Значение количественного определения прокальцитонина для диагностики септических осложнений у больных с аутоиммунными ревматическими заболеваниями. Клиническая лабораторная диагностика. 2013;(1):28-33. [Lapin SV, Maslyanskii AL, Lazareva NM, et al. The value of quantitative determination of procalcitonin for the diagnosis of septic complications in patients with autoimmune rheumatic diseases. Klinicheskaya laboratornaya diagnostika. 2013;(1):28-33. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Vincent JL, Moreno R, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med. 1996 Jul;22(7):707-10.</mixed-citation><mixed-citation xml:lang="en">Vincent JL, Moreno R, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med. 1996 Jul;22(7):707-10.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Scirе CA, Cavagna L, Perotti C, et al. Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol. 2006 Mar-Apr;24(2):123-8.</mixed-citation><mixed-citation xml:lang="en">Scirе CA, Cavagna L, Perotti C, et al. Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol. 2006 Mar-Apr;24(2):123-8.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Serio I, Arnaud L, Mathian A, et al. Can procalcitonin be used to distinguish between disease flare and infection in patients with systemic lupus erythematosus: a systematic literature review. Clin Rheumatol. 2014 Sep; 33(9):1209-15. doi: 10.1007/s10067-014-2738-4. Epub 2014 Jul 27.</mixed-citation><mixed-citation xml:lang="en">Serio I, Arnaud L, Mathian A, et al. Can procalcitonin be used to distinguish between disease flare and infection in patients with systemic lupus erythematosus: a systematic literature review. Clin Rheumatol. 2014 Sep; 33(9):1209-15. doi: 10.1007/s10067-014-2738-4. Epub 2014 Jul 27.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Okada Y, Minakami H, Tomomasa T, et al. Serum procalcitonin concentration in patients with Kawasaki disease. J Infect. 2004 Feb;48(2):199-205.</mixed-citation><mixed-citation xml:lang="en">Okada Y, Minakami H, Tomomasa T, et al. Serum procalcitonin concentration in patients with Kawasaki disease. J Infect. 2004 Feb;48(2):199-205.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Moosing F, Csernok E, Reinhold-Keller E, et al. Elevated procalcitonin levels in active Wegener's granulomatosis. J Rheumatol. 1998 Aug;25(8):1531-3.</mixed-citation><mixed-citation xml:lang="en">Moosing F, Csernok E, Reinhold-Keller E, et al. Elevated procalcitonin levels in active Wegener's granulomatosis. J Rheumatol. 1998 Aug;25(8):1531-3.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Morath C, Sis J, Haensch GM, et al. Procalcitonin as marker of infection in patients with Goodpasture's syndrome is misleading. Nephrol Dial Transplant. 2007 Sep;22(9):2701-4. Epub 2007 Jun 7.</mixed-citation><mixed-citation xml:lang="en">Morath C, Sis J, Haensch GM, et al. Procalcitonin as marker of infection in patients with Goodpasture's syndrome is misleading. Nephrol Dial Transplant. 2007 Sep;22(9):2701-4. Epub 2007 Jun 7.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Rosario C, Zandman-Goddard G, Meyron-Holtz E, et al. The Hyperferritinemic Syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013 Aug 22;11:185. doi: 10.1186/1741-7015-11-185.</mixed-citation><mixed-citation xml:lang="en">Rosario C, Zandman-Goddard G, Meyron-Holtz E, et al. The Hyperferritinemic Syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013 Aug 22;11:185. doi: 10.1186/1741-7015-11-185.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Nisten MW, Olingap P, The TH, et al. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med. 2000;28:458-61.</mixed-citation><mixed-citation xml:lang="en">Nisten MW, Olingap P, The TH, et al. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med. 2000;28:458-61.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Kettelhack C, Hohenberger P, Schulze G, et al. Induction of systemic serum procalcitonin and cardiocirculatory reactions after isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan. Crit Care Med. 2000 Apr;28(4):1040-6.</mixed-citation><mixed-citation xml:lang="en">Kettelhack C, Hohenberger P, Schulze G, et al. Induction of systemic serum procalcitonin and cardiocirculatory reactions after isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan. Crit Care Med. 2000 Apr;28(4):1040-6.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Zeni F, Vialon A, Tardy B, et al. Serum procalcitonin in sepsis: relation to severity and cytocines (TNF, IL-6, IL-8). 34th Interscience Conference of Antimicrobial Agents and Chemotherapy, 4–7 October 1994, Orlando.</mixed-citation><mixed-citation xml:lang="en">Zeni F, Vialon A, Tardy B, et al. Serum procalcitonin in sepsis: relation to severity and cytocines (TNF, IL-6, IL-8). 34th Interscience Conference of Antimicrobial Agents and Chemotherapy, 4–7 October 1994, Orlando.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Kaieda S, Yoshida N, Yamashita F, et al. Successful treatment of macrophage activation syndrome in a patient with dermatomyositis by combination with immunosuppressive therapy and plasmapheresis. Mod Rheumatol. 2015;25(6):962-6. doi: 10.3109/14397595.2013.844402. Epub 2013 Oct 21.</mixed-citation><mixed-citation xml:lang="en">Kaieda S, Yoshida N, Yamashita F, et al. Successful treatment of macrophage activation syndrome in a patient with dermatomyositis by combination with immunosuppressive therapy and plasmapheresis. Mod Rheumatol. 2015;25(6):962-6. doi: 10.3109/14397595.2013.844402. Epub 2013 Oct 21.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Uemura M, Huynh R, Kuo A, et al. Hemophagocytic Lymphohistiocytosis Complicating T- Cell Lymphoma in a Patient with HIV Infection. Case Rep Hematol. 2013;2013:687260. doi: 10.1155/2013/687260. Epub 2013 Aug 31.</mixed-citation><mixed-citation xml:lang="en">Uemura M, Huynh R, Kuo A, et al. Hemophagocytic Lymphohistiocytosis Complicating T- Cell Lymphoma in a Patient with HIV Infection. Case Rep Hematol. 2013;2013:687260. doi: 10.1155/2013/687260. Epub 2013 Aug 31.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Muller C, Manhardt LB, Willaschek C, et al. Beta-Blocker Therapy and Hemophagocytic Lymphohistiocytosis: A Case Report. Cardiol Res Pract. 2010;2010:912757. doi: 10.4061/2010/912757. Epub 2010 Jun 20.</mixed-citation><mixed-citation xml:lang="en">Muller C, Manhardt LB, Willaschek C, et al. Beta-Blocker Therapy and Hemophagocytic Lymphohistiocytosis: A Case Report. Cardiol Res Pract. 2010;2010:912757. doi: 10.4061/2010/912757. Epub 2010 Jun 20.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Захарова АЮ, Мутовина ЗЮ, Гордеев АВ, Шестакова ИН. Трудности диагностики гемофагоцитарного синдрома у пациентки с болезнью Стилла взрослых. Терапевтический архив. 2015;(5): 84-9. [Zakharova AYu, Mutovina ZYu, Gordeev AV, Shestakova IN. Difficulties in the diagnosis of hemophagocytic syndrome in a patient with adult Still's disease. Terapevticheskii arkhiv. 2015;(5):84-9. (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Захарова АЮ, Мутовина ЗЮ, Гордеев АВ, Шестакова ИН. Трудности диагностики гемофагоцитарного синдрома у пациентки с болезнью Стилла взрослых. Терапевтический архив. 2015;(5): 84-9. [Zakharova AYu, Mutovina ZYu, Gordeev AV, Shestakova IN. Difficulties in the diagnosis of hemophagocytic syndrome in a patient with adult Still's disease. Terapevticheskii arkhiv. 2015;(5):84-9. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Сhen DY, Chen YM, Ho WL, et al. Diagnostic value of procalcitonin for differentiation between bacterial infection and non-infectious inflammation in febrile patients with active adult-onset Still’s disease. Ann Rheum Dis. 2009 Jun;68(6):1074-5. doi: 10.1136/ard.2008.098335.</mixed-citation><mixed-citation xml:lang="en">Сhen DY, Chen YM, Ho WL, et al. Diagnostic value of procalcitonin for differentiation between bacterial infection and non-infectious inflammation in febrile patients with active adult-onset Still’s disease. Ann Rheum Dis. 2009 Jun;68(6):1074-5. doi: 10.1136/ard.2008.098335.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
